| University of Notre Dame Patent applications |
| Patent application number | Title | Published |
|---|
| 20110150934 | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer - Disclosed are compositions comprising non-viable ovarian tumor cells and/or ovarian cancer tissue cells useful as a vaccine for human ovarian cancer and/or for the inhibition of human ovarian tumor growth. Methods for preparing the ovarian cancer and/or tumor vaccines that comprise these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly ovarian tumor growth and ovarian cancers. The preparations may be defined as vaccines comprising human ovarian tumor tissue cells and/or human ovarian cancer cells. Preparations comprising the ovarian tissue cells together with an adjuvant are also provided. The ovarian tumor and/or ovarian cancer vaccines are demonstrated to significantly reduce the incidence of autochthonous ovarian cancer. | 06-23-2011 |
| 20110135690 | EXTRACELLULAR MATRIX ADJUVANT & METHODS FOR PREVENTION AND/OR INHIBITION OF OVARIAN TUMORS AND OVARIAN CANCER - Compositions suitable for use as ovarian cancer and/or tumor adjuvants in the preparation of ovarian cancer vaccines, particularly those vaccines useful in the treatment of human ovarian cancer, are provided. The ovarian cancer adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), tracer, or other solid or semi-solid preparation. Also disclosed are ovarian tumor inhibiting compositions that include extracellular matrix tissue adjuvants. | 06-09-2011 |
| 20100221824 | Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac - The present invention provides a method for transforming an insect genome that has a much enhanced transformation frequency. The vectors and plasmids employed in the method are further described as transposition vectors that include a minimal amount of nucleotide sequence homologous to a 5′ region and a 3′ region of a native piggyBac nucleic acid sequence. The transformed cells or embryos may also be developed into transgenic organisms. Disclosed are minimal piggyBac-based plasmid constructs that comprises a minimal nucleic acid sequence homologous to a 5′ end of a piggyBac nucleic acid sequence (about 60-80 bp, particularly 66 bp) and a relatively long (300 to about 380 bp, particularly 311 by or 378 bp) continuous nucleic acid sequence homologous to a 3′ end of a piggyBac native nucleic acid sequence. Methods employing these constructs include the use of a helper plasmid. Transformation frequencies employing the constructs are enhanced 100-fold or higher over that transformation frequency obtained using other than the herein described constructs. | 09-02-2010 |
| 20100196906 | Accelerated Progression Relapse Test - Disclosed is an accelerated progression relapse test for use in the prognosis of disease states. According to the test disclosed herein, it can be determined whether a patient would benefit from treatment for a disease state or whether the patient's prognosis would not have a high probability of benefit with additional treatment. In particular, the test is useful in determining a patient's prognosis for cancer (breast, colon, lung, etc). For example, the test of the invention can be used to determine the prognosis for estrogen receptor positive (ER+) breast cancer patients. In the test for ER+ breast cancer patients, four genetic probes are employed that target MK167, CDC6, and SPAG5 gene products. The ER+ breast cancer test stratifies a patient population into two groups, with the low gene expression group identifying a group that is less likely to benefit from additional treatment measures, and a high gene expression group, identifying a group more likely to benefit from additional treatment measures. | 08-05-2010 |
| 20090220461 | Metastasis inhibition preparations and methods - Disclosed are compositions and pharmaceutical preparations suitable for inhibiting metastasis of a malignant cancer in an animal. Methods for inhibiting and/or eliminating metastasis in an animal are also provided. In some embodiments, the preparations and compositions comprise a whole cell tumor preparation comprising tumor tissue cells and tumor connective tissue stroma. The disclosure also provides methods for preparing the preparations and pharmaceutical preparations. Inhibition of metastasis of malignant prostate cancer to the lung is shown in vivo. | 09-03-2009 |
